Abstract
Leachables from single-use bioprocess containers (BPCs) are a source of process-related impurities that have the potential to alter product quality of biotherapeutics and impact patient health. Leachables often exist at very low concentrations making it difficult to detect their presence and challenging to assess their impact on protein quality. A small-scale stress model based on assessing protein stability was developed to evaluate the potential risks associated with storing biotherapeutics in disposable bags caused by the presence of leachables. Small-scale BPCs were filled with protein solution at high surface area-to-volume ratios (≥ 3x the surface area-to-volume ratio of manufacturing scale BPCs) and incubated at stress temperatures (e.g. 25°C or 30°C for up to 12 weeks) along with an appropriate storage vessel (e.g., glass vial or stainless steel) as a control for side-by-side comparison. Changes in protein size variants measured by size exclusion chromatography (SEC), capillary electrophoresis, and particle formation for two monoclonal antibodies (mAbs) using both the small scale stress model and a control revealed a detrimental effect of gamma irradiated BPC on protein aggregation and significant BPC batch-to-batch differences. It was found that preincubation of the empty BPCs prior to protein storage improved protein stability suggesting the presence of volatile or heat sensitive leachables. In addition, increasing the polysorbate 20 concentration lowered, but did not completely mitigate, the leachable-protein interactions indicating the presence of a hydrophobic leachable. Overall, this model can inform the risk of BPC leachables on bio-therapeutics during routine manufacturing and assist in making decisions on the selection of a suitable BPC for the manufacturing process via assessing changes in product quality.
- disposable storage bags
- leachable induced aggregation
- monoclonal antibody
- risk assessment
- single-use bioprocess containers
- stability
- Received November 29, 2015.
- Accepted May 28, 2016.
- Copyright © 2016, Parenteral Drug Association
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.